[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myopic-choroidal-neovascularisation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myopic-choroidal-neovascularisation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100593679","the-treatment-burden-of-myopic-choroidal-neovascularization-100593679",false,"NCT07009574","The Treatment Burden of Myopic Choroidal Neovascularization","Factors Associated to Treatment Burden in Patients Affected by Myopic Choroidal Neovascularization","mCNV burden","Inclusion Criteria:\n\n* axial length\\>26 mm or refractive error (spherical equivalent) \\\u003C-6 Diopters\n* clinical changes typical of Pathologic myopia\n* diagnosis of subfoveal or juxtafoveal treatment-naïve myopic choroidal neovascularization (mCNV)\n* only one eye per patient was included in the analysis, in cases of patients treated bilaterally only the first eye treated was included\n\nExclusion Criteria:\n\n* Extrafoveal mCNV location\n* Other retinal diseases\n* any inflammatory condition which may cause CNV including multifocal choroiditis, puntate inner choroidopathy and white dot syndrome\n* previous ocular surgery (except for cataract extraction performed before the baseline visit)\n* inferior quality imaging","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Pathologic myopia (PM) is characterized by progressive eye elongation associated with degenerative changes in the retinal and choroidal tissue. Myopic choroidal neovascularization (mCNV) is a well-known complication of PM, occurring in 5-11% of cases and representing a main cause of visual impairment in working people under the age of 50.\n\nThe management of patients affected by active mCNV have been revolutionized by the advent of intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs.\n\nPatients affected by mCNV needs intravitreal injections and visits to assess the need of retreatment with assiduity. It represents a significant burden for patients, caregivers as well as medical equipe.\n\nThe aim of this study is to investigate the factors associated with the number of anti-VEGF injections and hospital visits necessary to get mCNV disease stabilization and to identify predictive factors of treatment burden.",[25,26,27],"Myopic Choroidal Neovascularisation","Anti-VEGF Treatment","Burden",[29,30,31,32,33],"mcnv","anti-vegf","myopic maculopathy","choroidal neovascularization","myopia","NOT_YET_RECRUITING","2025-06-03",{"date":37,"type":38},"2025-06-06","ACTUAL",{"date":40,"type":21},"2025-06-01",{"date":42,"type":21},"2025-12-15",{"name":44,"class":45},"Policlinico Gaspare Rodolico - San Marco Catania","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":46},"100583667","early-phase-1-effectiveness-of-intravitreal-injection-of-aflibercept-8-mg-in-resistant-diabetic-macular-edema-retinal-vein-occlusion-and-myopic-choroidal-neovascularisation-patients-100583667","NCT06879301","Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema and Retinal Vein Occlusion Patients","Inclusion Criteria:\n\nThis study included resistant centrally involved diabetic macular edema (DME) cases\n\n\\-\n\nExclusion Criteria:\n\n1. Patients with a history of intraocular surgery\n2. coincident retinal pathology such as retinal vascular occlusion, CNV due to age-related macular degeneration, angioid streaks, trauma, and choroiditis were excluded from the study.\n3. patients who received other lines of treatment for DME, such as laser photocoagulation, intravitreal injection of steroids\n4. patients known to be glaucomatous or have an IOP ≥20 mmHg were also excluded.\n\n   \\-",true,"20 Years","60 Years",{"count":58,"type":21},60,"INTERVENTIONAL",[61],"EARLY_PHASE1","Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys, and heart, seriously affecting organ function. Nowadays, the quality of life of people has improved significantly, eating habits have changed, sugar intake is increasing, and the number of patients with DM is increasing. Statistics show that in 2017, the number of patients with DM worldwide reached 425 million (aged 20-79 years), which will exceed 600 million in 30 years; moreover, patients in low- and middle-income countries, such as China and India, account for 80 percent of the total DM population (1). According to the WHO, patients with DM worldwide increased to 366 million in 2011, which is expected to increase to 500 million in 2025, with more than 150 million patients experiencing ocular complications, such as diabetic retinopathy (DR) (2, 3). DR is a form of ocular microangiopathy and the most serious DM-related complication; it seriously endangers the health of patients with DM (4). DR pathogenesis includes increased endothelial cells in the eye capillaries, increased intimal thickness, damaged pericytes, microangioma, and damaged blood-retina barrier due to increased permeability of the blood vessels, microvascular obstruction, and neovascularization (NV) (5, 6). Currently, the prevalence of DR is 34.6% worldwide; however, it is higher in some developed countries, reaching 40.3% (7). The proportion of patients with type 1 and 2 DM suffering from blindness due to DR is 3.6% and 1.6%, respectively (8). DR is associated with significantly reduced living standards, huge medical costs, and increased social burden (9, 10).\n\nMany anti-vascular endothelial growth factor (VEGF) drugs exist; however, the use of therapeutic drugs is strictly controlled. The main drugs recommended for treating DM-related visual complications are ranibizumab and aflibercept.",[64,65,25],"Diabetic Macular Edema (DME)","Retinal Vein Occlusion (RVO)",[67,68],"Aflibercept 8 mg","diabetic macular edema","2025-03-11",{"date":71,"type":38},"2025-03-17",{"date":73,"type":21},"2025-10-19",{"date":75,"type":21},"2025-12-19",{"name":77,"class":45},"Tanta University"]